IL127714A - שמוש בטופירמט או תולדות שלו להכנת תכשיר לטפול בהפרעות של מחלת הדכאון המאני הביפולרית - Google Patents

שמוש בטופירמט או תולדות שלו להכנת תכשיר לטפול בהפרעות של מחלת הדכאון המאני הביפולרית

Info

Publication number
IL127714A
IL127714A IL12771497A IL12771497A IL127714A IL 127714 A IL127714 A IL 127714A IL 12771497 A IL12771497 A IL 12771497A IL 12771497 A IL12771497 A IL 12771497A IL 127714 A IL127714 A IL 127714A
Authority
IL
Israel
Prior art keywords
treatment
formula
compound
topiramate
alkyl
Prior art date
Application number
IL12771497A
Other languages
English (en)
Other versions
IL127714A0 (en
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL127714A0 publication Critical patent/IL127714A0/xx
Publication of IL127714A publication Critical patent/IL127714A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/442—Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
    • H04N21/44213—Monitoring of end-user related data
    • H04N21/44222—Analytics of user selections, e.g. selection of programs or purchase activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Social Psychology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL12771497A 1996-06-28 1997-06-24 שמוש בטופירמט או תולדות שלו להכנת תכשיר לטפול בהפרעות של מחלת הדכאון המאני הביפולרית IL127714A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2085096P 1996-06-28 1996-06-28
US08/881,008 US5753693A (en) 1996-06-28 1997-06-23 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
PCT/US1997/010949 WO1998000123A1 (en) 1996-06-28 1997-06-24 Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders

Publications (2)

Publication Number Publication Date
IL127714A0 IL127714A0 (en) 1999-10-28
IL127714A true IL127714A (he) 2004-08-31

Family

ID=26693960

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12771497A IL127714A (he) 1996-06-28 1997-06-24 שמוש בטופירמט או תולדות שלו להכנת תכשיר לטפול בהפרעות של מחלת הדכאון המאני הביפולרית

Country Status (21)

Country Link
US (1) US5753693A (he)
EP (1) EP0932398B1 (he)
JP (1) JP2002515875A (he)
KR (1) KR20000022233A (he)
CN (1) CN1224350A (he)
AP (1) AP1401A (he)
AT (1) ATE330593T1 (he)
AU (1) AU739363B2 (he)
BR (1) BR9712783A (he)
CA (1) CA2258895C (he)
CZ (1) CZ297342B6 (he)
DE (1) DE69736183T2 (he)
ES (1) ES2267144T3 (he)
HU (1) HUP0003381A3 (he)
IL (1) IL127714A (he)
NO (1) NO317641B1 (he)
NZ (1) NZ333565A (he)
RU (1) RU2185824C2 (he)
SK (1) SK180498A3 (he)
WO (1) WO1998000123A1 (he)
ZA (1) ZA975773B (he)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1143917E (pt) * 1998-11-17 2004-06-30 Ortho Mcneil Pharm Inc Derivados anticonvulsionantes uteis no tratamento da perturbacao de stress pos-traumatico
JP2004517029A (ja) * 1998-12-03 2004-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 精神分裂病の処置のためのトピラメート及び関連誘導体
DE60021252T2 (de) 1999-02-08 2006-05-18 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsiva zur behandlung von autismus
WO2000050020A2 (en) 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6583172B1 (en) 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
DK1187603T3 (da) 1999-06-14 2007-12-17 Vivus Inc Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
AU2001280865A1 (en) * 2000-08-02 2002-02-13 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
DE60142632D1 (de) 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2578407A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
EP1881959A1 (en) * 2005-05-20 2008-01-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008061226A2 (en) 2006-11-17 2008-05-22 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
CN102218044A (zh) * 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Also Published As

Publication number Publication date
AU739363B2 (en) 2001-10-11
CZ297342B6 (cs) 2006-11-15
ZA975773B (en) 1998-12-28
CN1224350A (zh) 1999-07-28
DE69736183T2 (de) 2007-04-26
CA2258895A1 (en) 1998-01-08
WO1998000123A1 (en) 1998-01-08
BR9712783A (pt) 2000-10-24
NO986051D0 (no) 1998-12-22
EP0932398B1 (en) 2006-06-21
AP9801427A0 (en) 1998-12-31
IL127714A0 (en) 1999-10-28
US5753693A (en) 1998-05-19
RU2185824C2 (ru) 2002-07-27
NZ333565A (en) 2000-07-28
AU3409697A (en) 1998-01-21
CA2258895C (en) 2006-06-06
DE69736183D1 (de) 2006-08-03
HUP0003381A3 (en) 2001-12-28
EP0932398A1 (en) 1999-08-04
AP1401A (en) 2005-04-29
CZ427798A3 (cs) 1999-08-11
NO986051L (no) 1999-02-23
HUP0003381A2 (hu) 2001-05-28
SK180498A3 (en) 2000-03-13
KR20000022233A (ko) 2000-04-25
ATE330593T1 (de) 2006-07-15
NO317641B1 (no) 2004-11-29
ES2267144T3 (es) 2007-03-01
JP2002515875A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
IL127714A (he) שמוש בטופירמט או תולדות שלו להכנת תכשיר לטפול בהפרעות של מחלת הדכאון המאני הביפולרית
US4366172A (en) 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
US3975532A (en) Hexahydro-1H-furo(3,4-c) pyrrole compounds for treating pain
US4314944A (en) 4-Aminoalkyl-7-hydroxy-2(3H)-indolones
HU214321B (hu) Eljárás tramadol-N-oxid-származék, enantiomerjei és ezeket hatóanyagként tartalmazó gyógyszerkészítmények előállítására
FI93116C (fi) Stereospesifinen menetelmä furo/3,4-c/pyridiini-enantiomeerien valmistamiseksi
US3717641A (en) Derivatives of dibenzo cycloocten-5,11-imine
CA1094071A (en) Trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3- b] indoles
US6133258A (en) Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
US4581172A (en) Substituted pyrimido[6,1-a]isoquinolin-4-ones,pyrimido[6,1-a]benzozepin-4-ones and pyrimido[6,1-a]benzodiazepin-4-ones useful for prevention of thromboses and treating hypertension
GB2418425A (en) 3-Acylaminocaprolactams containing a mono- or poly-cyclic cyclo-alkane or -alkene group in the acyl moiety for treatment of inflammatory disorders
US3917704A (en) Alpha-aminoalkyl-4-hydroxy-3-alkylsulfonylmethylbenzyl alcohols
FI85142B (fi) Foerfarande foer framstaellning av ergolinestrar.
US5438069A (en) Glucohydrolase inhibitors useful as antidiabetic agents
US3435041A (en) 2-anilinoquinolines
IL108369A (he) תכשירי רוקחות להגברת רגישות של גידולים ממאירים חסיני תר ופות המכילים דיארילאלקיל פיפרידינים
US4421768A (en) Fluorinated diamino-heptene and-heptyne derivatives
US4250180A (en) Method of treating arrhythmia
JPH072637B2 (ja) キノリジン誘導体を含有する医薬組成物
US3796715A (en) 8-alkoxy-3,4-dihydroisoquinolines
US3910917A (en) 1-Oxo-hexahydroacridines
US3560620A (en) Induction of fibrinolysis
FI96422B (fi) Furo/3,4-c/pyridiinijohdosten asymmetrinen synteesi
US4001259A (en) 3,6-diamino-3,4-dihydro-2-pyridones
US4340601A (en) Dopaminergic isoquinolines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees